Kirsty

Insulin Aspart, the active ingredient in Kirsty, is a rapid‑acting insulin analog presented as a solution for subcutaneous use. It treats hyperglycemia in both type 1 and type 2 diabetes mellitus, helping patients achieve post‑prandial glucose control.

GNH USA supplies Kirsty as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin Aspart is a rapid‑acting insulin used to manage blood glucose in diabetes mellitus. - Type 1 diabetes mellitus: provides mealtime glucose control and reduces post‑prandial hyperglycemia. - Type 2 diabetes mellitus: used as part of intensive insulin regimens to achieve target glycemic levels. - Insulin pump therapy: serves as a rapid‑acting bolus insulin for continuous subcutaneous insulin infusion devices.

Insulin Aspart may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypoglycemia: low blood glucose levels, the most frequent reaction. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with insulin therapy. - Nausea: feeling of sickness or upset stomach. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Severe hypoglycemia: neurological symptoms requiring immediate assistance. - Allergic reactions: rash, urticaria, or anaphylaxis in rare cases. - Lipohypertrophy: abnormal fat accumulation at injection sites. - Serum insulin antibodies: may alter insulin action.

When using Insulin Aspart, several precautions should be observed to ensure safe and effective therapy. - Dose adjustment: tailor the dose to carbohydrate intake, blood glucose readings, and physical activity. - Renal impairment: monitor glucose closely and consider dose reduction. - Hepatic impairment: use with caution and observe for altered insulin clearance. - Pregnancy and lactation: only use if benefits outweigh potential risks. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart can interact with other medicines, affecting glucose control or increasing adverse event risk.

Major Interactions (Avoid): - Beta‑blockers: may mask symptoms of hypoglycemia. - Monoamine oxidase inhibitors: can potentiate insulin’s glucose‑lowering effect. - Glucagon: concurrent use may lead to unpredictable glucose responses.

Moderate Interactions (Monitor Closely): - Thiazolidinediones: increased risk of fluid retention and edema. - Diuretics: may influence potassium balance and affect insulin action. - Oral contraceptives: may alter insulin requirements and glucose control.